Eli Lilly's weightloss drug helps reduce sleep apnoea
The Eli Lilly and Co (NYSE:LLY) weightloss drug Tirzepatide, known as Zepbound and Mounjaro, has also been shown in two trials to help improve the symptoms of sleep apnea. Tirzepatide "meaningfully...
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients
Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday.
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trials
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.
Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bank
A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, t...
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analyst...
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly wowed patients and investors with its top-performing weight loss drugs. The big pharma company's stock has climbed in the triple digits over the past year thanks to its revenue growth.
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.
Wegovy's heart benefits are not just linked with weight loss, new study suggests
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, acc...
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Eli Lilly is having trouble keeping up with the demand for Zepbound. This medicine could go on to break sales records.
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the...
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.
Why There's Limited Supply Of The Weight Loss Drug Zepbound
Zepound—an Eli Lilly-produced drug that has become a popular alternative to other weight loss drugs such as Wegovy and Ozempic—is facing a shortage in the U.S. of some of its doses because of the g...
Related Companies